Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL889 in Adult Patients With Sickle Cell Disease
NCT04285827Phase 1Completed
- Sponsor
- CSL Limited
- Start
- May 2021
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 1, open-label trial of hemopexin in sickle cell disease (SCD), sponsored by CSL Limited. Primary endpoints: Treatment-Emergent Adverse Events at 32 days, TEAEs by Severity at 32 days and 1 more. Started May 2021; status: completed.
02
Drugs
hemopexin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04285827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04285827.